Gland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving profitability. Future growth is anticipated from capacity expansions and new product lines. The company’s contract development and manufacturing business is also expanding. Investors are watching Gland Pharma’s growth prospects.
Fed’s Jefferson urges patience on rates; Kashkari sees more hikes ahead
Federal Reserve Vice Chair Philip Jefferson stated that he sees no immediate need for further interest rate adjustments. He emphasized that future decisions would depend